drugset / Trial / NCT06220838
Study SC-101 in Subjects With Advanced Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, pharmacokinetics, and anti-cancer efficacy of SC-101 in subjects with advanced or metastatic solid tumors.
Timeline
- Start
- 2024-02-02
- Primary completion
- 2026-03
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SC-101 | Small interfering RNA (siRNA) | — | Intravenous |